Terms: = Breast cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
16 results:
1. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
[TBL] [Abstract] [Full Text] [Related]
2. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
3. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
4. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract] [Full Text] [Related]
5. Mechanoactivation of NOX2-generated ROS elicits persistent TRPM8 Ca
Pratt SJP; Lee RM; Chang KT; Hernández-Ochoa EO; Annis DA; Ory EC; Thompson KN; Bailey PC; Mathias TJ; Ju JA; Vitolo MI; Schneider MF; Stains JP; Ward CW; Martin SS
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26008-26019. PubMed ID: 33020304
[TBL] [Abstract] [Full Text] [Related]
6. clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
Banys-Paluchowski M; Milde-Langosch K; Fehm T; Witzel I; Oliveira-Ferrer L; Schmalfeldt B; Müller V
Breast Cancer Res Treat; 2020 Jan; 179(2):403-414. PubMed ID: 31646390
[TBL] [Abstract] [Full Text] [Related]
7. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract] [Full Text] [Related]
8. Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; Shoji M; Murata T
Int J Oncol; 2016 Aug; 49(2):812-22. PubMed ID: 27221776
[TBL] [Abstract] [Full Text] [Related]
9. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
[TBL] [Abstract] [Full Text] [Related]
10. No clinical utility of kras variant rs61764370 for ovarian or breast cancer.
; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Apicella C; Arndt V; Arnold N; Arun BK; Arver B; Ashworth A; ; Baglietto L; Balleine R; Bandera EV; Barrowdale D; Bean YT; Beckmann L; Beckmann MW; Benitez J; Berger A; Berger R; Beuselinck B; Bisogna M; Bjorge L; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Brand JS; Brauch H; ; Brenner H; Brinton L; Brooks-Wilson A; Bruinsma F; Brunet J; Brüning T; Budzilowska A; Bunker CH; Burwinkel B; Butzow R; Buys SS; Caligo MA; Campbell I; Carter J; Chang-Claude J; Chanock SJ; Claes KBM; Collée JM; Cook LS; Couch FJ; Cox A; Cramer D; Cross SS; Cunningham JM; Cybulski C; Czene K; Damiola F; Dansonka-Mieszkowska A; Darabi H; de la Hoya M; deFazio A; Dennis J; Devilee P; Dicks EM; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Silva IDS; du Bois A; Dumont M; Dunning AM; Duran M; Easton DF; Eccles D; Edwards RP; Ehrencrona H; Ejlertsen B; Ekici AB; Ellis SD; ; Engel C; Eriksson M; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Fontaine A; Fortuzzi S; Fostira F; Fridley BL; Friebel T; Friedman E; Friel G; Frost D; Garber J; García-Closas M; Gayther SA; ; ; Gentry-Maharaj A; Gerdes AM; Giles GG; Glasspool R; Glendon G; Godwin AK; Goodman MT; Gore M; Greene MH; Grip M; Gronwald J; Gschwantler Kaulich D; Guénel P; Guzman SR; Haeberle L; Haiman CA; Hall P; Halverson SL; Hamann U; Hansen TVO; Harter P; Hartikainen JM; Healey S; ; Hein A; Heitz F; Henderson BE; Herzog J; T Hildebrandt MA; Høgdall CK; Høgdall E; Hogervorst FBL; Hopper JL; Humphreys K; Huzarski T; Imyanitov EN; Isaacs C; Jakubowska A; Janavicius R; Jaworska K; Jensen A; Jensen UB; Johnson N; Jukkola-Vuorinen A; Kabisch M; Karlan BY; Kataja V; Kauff N; ; Kelemen LE; Kerin MJ; Kiemeney LA; Kjaer SK; Knight JA; Knol-Bout JP; Konstantopoulou I; Kosma VM; Krakstad C; Kristensen V; Kuchenbaecker KB; Kupryjanczyk J; Laitman Y; Lambrechts D; Lambrechts S; Larson MC; Lasa A; Laurent-Puig P; Lazaro C; Le ND; Le Marchand L; Leminen A; Lester J; Levine DA; Li J; Liang D; Lindblom A; Lindor N; Lissowska J; Long J; Lu KH; Lubinski J; Lundvall L; Lurie G; Mai PL; Mannermaa A; Margolin S; Mariette F; Marme F; Martens JWM; Massuger LFAG; Maugard C; Mazoyer S; McGuffog L; McGuire V; McLean C; McNeish I; Meindl A; Menegaux F; Menéndez P; Menkiszak J; Menon U; Mensenkamp AR; Miller N; Milne RL; Modugno F; Montagna M; Moysich KB; Müller H; Mulligan AM; Muranen TA; Narod SA; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Neven P; Nielsen FC; Nielsen SF; Nordestgaard BG; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olson SH; Oosterwijk JC; Orlow I; Orr N; Orsulic S; Osorio A; Ottini L; Paul J; Pearce CL; Pedersen IS; Peissel B; Pejovic T; Pelttari LM; Perkins J; Permuth-Wey J; Peterlongo P; Peto J; Phelan CM; Phillips KA; Piedmonte M; Pike MC; Platte R; Plisiecka-Halasa J; Poole EM; Poppe B; Pylkäs K; Radice P; Ramus SJ; Rebbeck TR; Reed MWR; Rennert G; Risch HA; Robson M; Rodriguez GC; Romero A; Rossing MA; Rothstein JH; Rudolph A; Runnebaum I; Salani R; Salvesen HB; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Schneeweiss A; Schoemaker MJ; Schrauder MG; Schumacher F; Schwaab I; Scuvera G; Sellers TA; Severi G; Seynaeve CM; Shah M; Shrubsole M; Siddiqui N; Sieh W; Simard J; Singer CF; Sinilnikova OM; Smeets D; Sohn C; Soller M; Song H; Soucy P; Southey MC; Stegmaier C; Stoppa-Lyonnet D; Sucheston L; ; Swerdlow A; Tangen IL; Tea MK; Teixeira MR; Terry KL; Terry MB; Thomassen M; Thompson PJ; Tihomirova L; Tischkowitz M; Toland AE; Tollenaar RAEM; Tomlinson I; Torres D; Truong T; Tsimiklis H; Tung N; Tworoger SS; Tyrer JP; Vachon CM; Van 't Veer LJ; van Altena AM; Van Asperen CJ; van den Berg D; van den Ouweland AMW; van Doorn HC; Van Nieuwenhuysen E; van Rensburg EJ; Vergote I; Verhoef S; Vierkant RA; Vijai J; Vitonis AF; von Wachenfeldt A; Walsh C; Wang Q; Wang-Gohrke S; Wappenschmidt B; Weischer M; Weitzel JN; Weltens C; Wentzensen N; Whittemore AS; Wilkens LR; Winqvist R; Wu AH; Wu X; Yang HP; Zaffaroni D; Pilar Zamora M; Zheng W; Ziogas A; Chenevix-Trench G; Pharoah PDP; Rookus MA; Hooning MJ; Goode EL
Gynecol Oncol; 2016 May; 141(2):386-401. PubMed ID: 25940428
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract] [Full Text] [Related]
12. cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract] [Full Text] [Related]
13. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
Mendes-Pereira AM; Sims D; Dexter T; Fenwick K; Assiotis I; Kozarewa I; Mitsopoulos C; Hakas J; Zvelebil M; Lord CJ; Ashworth A
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2730-5. PubMed ID: 21482774
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
15. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract] [Full Text] [Related]
16. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and kras mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract] [Full Text] [Related]
